Latest News in the pharma Industry

Research & Development

Positive results from 12-month Phase III safety study of Revefenacin in patients with COPD

Positive results from 12-month Phase III safety study of Revefenacin in patients with COPD

20 Jul 2017

These data, combined with positive results from two Phase III efficacy studies, support NDA filing planned for fourth quarter of 2017.

Read more 
Onyx helps to accelerate TopiVert’s compounds to clinic

Onyx helps to accelerate TopiVert’s compounds to clinic

19 Jul 2017

With support from the CRO, TopiVert has been able to accelerate scale-up and produce GMP batches, which are now being used in clinical trials.

Read more 
Shire expands broad monoclonal antibody research platform

Shire expands broad monoclonal antibody research platform

18 Jul 2017

Shire obtains worldwide license to pursue development and commercialization of a novel, potentially differentiated, pre-clinical bi-specific antibody candidate for Hemophilia A.

Read more 
Amgen and Array BioPharma announce preclinical license and collaboration agreement in inflammation

Amgen and Array BioPharma announce preclinical license and collaboration agreement in inflammation

18 Jul 2017

Array to advance preclinical program for autoimmune disorders; Amgen responsible for clinical development and worldwide commercialization.

Read more 
Alzheon presents new data for ALZ-801 on novel MOA and long-term clinical efficacy at the AAIC

Alzheon presents new data for ALZ-801 on novel MOA and long-term clinical efficacy at the AAIC

17 Jul 2017

Presentations highlight recent discovery of inhibition of formation of toxic beta amyloid oligomers and new insights for Precision Medicine approach for ALZ-801 targeting APOE4 carriers.

Read more 
Ground-breaking preclinical data to be presented at AAIC 2017

Ground-breaking preclinical data to be presented at AAIC 2017

16 Jul 2017

KalGene’s Alzheimer’s therapeutics candidate, licensed from the NRC (KAL-ABP-BBB), crosses the blood-brain barrier, and reduces amyloid-beta burden in a transgenic rat model after a 4-week treatment.

Read more 
Novartis confirms 5-year data for Cosentyx reinforcing sustained efficacy and safety profile in psoriasis

Novartis confirms 5-year data for Cosentyx reinforcing sustained efficacy and safety profile in psoriasis

16 Jul 2017

Cosentyx continues to demonstrate it can provide what psoriasis patients want - a life with clear skin.

Read more 
Novartis CAR-T cell therapy CTL019 recommended for FDA approval

Novartis CAR-T cell therapy CTL019 recommended for FDA approval

13 Jul 2017

A BLA for this indication is under FDA priority review; if approved, CTL019 could become first CAR-T cell therapy available.

Read more 
FDA approves Blincyto to treat relapsed or refractory B-cell precursor acute lymphoblastic leukemia

FDA approves Blincyto to treat relapsed or refractory B-cell precursor acute lymphoblastic leukemia

12 Jul 2017

Blincyto is the first and only Bispecific T cell Engager (BiTE) immunotherapy to demonstrate superior overall survival versus standard of care chemotherapy.

Read more 
Erytech collaborates with Queen’s University to advance product candidate for rare metabolic disorders

Erytech collaborates with Queen’s University to advance product candidate for rare metabolic disorders

12 Jul 2017

The collaboration will leverage the expertise of Queen’s University and Erytech’s ERYCAPS platform technology.

Read more 
New data reinforce the effectiveness of Viberzi  to treat the symptoms associated with IBS-D

New data reinforce the effectiveness of Viberzi to treat the symptoms associated with IBS-D

11 Jul 2017

Viberzi proven safe and effective in patients who reported inadequate response to prior loperamide use.

Read more 
Daiichi Sankyo, Max Planck Innovation and Lead Discovery Center announce cancer research collaboration

Daiichi Sankyo, Max Planck Innovation and Lead Discovery Center announce cancer research collaboration

11 Jul 2017

Parties to optimize certain novel compounds that target cancer cell transcription and proliferation.

Read more